Register for our free email digests:
Latest From Zimmer Knee Creations Inc.
With the surprise announcement that Zimmer, the number three player, will acquire Biomet, the number five player, in a transaction valued at $13 billion, a transformation in the orthopedic industry is underway. Most of the major orthopedic manufacturers are primed with a war chest of cash to make acquisitions for future growth, and as health care reform unfolds, companies are positioning themselves to compete in a changing world where “bigger is better.”
While Zimmer continues to build its knee osteoarthritis early-intervention product line, most recently by acquiring Knee Creations LLC and its Subchondroplasty procedure, controversial new clinical practice guidelines have been released that recommend against the use of hyaluronic acid injections (viscosupplementation) for early knee OA.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Paion GMBH
- Western Europe
- Parent & Subsidiaries
- Paion AG
- Senior Management
Wolfgang Sohngen, MD, PhD, CEO
Abdelghani Omari, CFO
Mariola Sohngen, MD, PhD, CMO
Jürgen Raths, MD, COO
- Contact Info
Phone: (49) 241 4453 0
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.